## Michel Boussinesq

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/627901/publications.pdf

Version: 2024-02-01

120 papers 29,157 citations

66343 42 h-index 20358 116 g-index

122 all docs 122 docs citations

122 times ranked 44582 citing authors

#	Article	IF	CITATIONS
1	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, $1990 = 1000$ a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
2	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
3	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
4	The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. PLoS Neglected Tropical Diseases, 2014, 8, e2865.	3.0	796
5	Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet, The, 1997, 350, 18-22.	13.7	554
6	River Blindness: A Success Story under Threat?. PLoS Medicine, 2006, 3, e371.	8.4	194
7	Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Science Translational Medicine, 2015, 7, 286re4.	12.4	184
8	Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2008, 8, 310-322.	9.1	177
9	Th2 Cytokines Are Associated with Reduced Worm Burdens in a Human Intestinal Helminth Infection. Journal of Infectious Diseases, 2003, 188, 1768-1775.	4.0	175
10	Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Parasites and Vectors, 2003, 2, S4.	1.3	149
11	Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet, The, 2002, 360, 203-210.	13.7	144
12	A Test-and-Not-Treat Strategy for Onchocerciasis in <i>Loa loa</i> –Endemic Areas. New England Journal of Medicine, 2017, 377, 2044-2052.	27.0	135
13	Epilepsy in Onchocerciasis Endemic Areas: Systematic Review and Meta-analysis of Population-Based Surveys. PLoS Neglected Tropical Diseases, 2009, 3, e461.	3.0	130
14	Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infectious Diseases of Poverty, 2016, 5, 66.	3.7	125
15	Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas. Parasitology Today, 1996, 12, 448-450.	3.0	114
16	The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study. Lancet Infectious Diseases, The, 2018, 18, 1278-1286.	9.1	114
17	T Helper Cell Type 2 Responsiveness Predicts Future Susceptibility to Gastrointestinal Nematodes in Humans. Journal of Infectious Diseases, 2004, 190, 1804-1811.	4.0	110
18	Allergen-specific IgE and IgG4 are markers of resistance and susceptibility in a human intestinal nematode infection. Microbes and Infection, 2005, 7, 990-996.	1.9	104

#	Article	IF	Citations
19	Intensity of Intestinal Infection with Multiple Worm Species Is Related to Regulatory Cytokine Output and Immune Hyporesponsiveness. Journal of Infectious Diseases, 2008, 197, 1204-1212.	4.0	104
20	Genetic Selection of Low Fertile Onchocerca volvulus by Ivermectin Treatment. PLoS Neglected Tropical Diseases, 2007, 1, e72.	3.0	97
21	Population biology of human onchocerciasis. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 809-826.	4.0	95
22	Age―and Infection Intensity–Dependent Cytokine and Antibody Production in Human Trichuriasis: The Importance of IgE. Journal of Infectious Diseases, 2002, 185, 665-672.	4.0	94
23	Safety of high-dose ivermectin: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2020, 75, 827-834.	3.0	93
24	Alternative treatment strategies to accelerate the elimination of onchocerciasis. International Health, 2018, 10, i40-i48.	2.0	89
25	Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. PLoS Neglected Tropical Diseases, 2017, 11, e0005816.	3.0	87
26	Demographic Impact of Epilepsy in Africa: Results of a 10â€year Cohort Study in a Rural Area of Cameroon. Epilepsia, 2003, 44, 956-963.	5.1	81
27	Human infection patterns and heterogeneous exposure in river blindness. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15265-15270.	7.1	77
28	Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16716-16721.	7.1	77
29	P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Molecular and Biochemical Parasitology, 2008, 158, 101-111.	1.1	75
30	Excess mortality associated with loiasis: a retrospective population-based cohort study. Lancet Infectious Diseases, The, 2017, 17, 108-116.	9.1	70
31	Case-control Studies on the Relationship between Onchocerciasis and Epilepsy: Systematic Review and Meta-analysis. PLoS Neglected Tropical Diseases, 2013, 7, e2147.	3.0	69
32	Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. Parasites and Vectors, 2016, 9, 581.	2.5	59
33	Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West Africa. PLoS Neglected Tropical Diseases, 2016, 10, e0004328.	3.0	59
34	Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis Control. Parasites and Vectors, 2004, 3, 7.	1.3	57
35	Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness. Clinical Infectious Diseases, 2017, 65, 2026-2034.	5.8	55
36	How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control. Clinical Infectious Diseases, 2018, 66, S267-S274.	5.8	55

#	Article	IF	CITATIONS
37	Analysis of the mdr-1 Gene in Patients Co-Infected with Onchocerca volvulus and Loa loa Who Experienced a Post-Ivermectin Serious Adverse Event. American Journal of Tropical Medicine and Hygiene, 2010, 83, 28-32.	1.4	52
38	Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13Âyears of ivermectin. Infectious Diseases of Poverty, 2018, 7, 114.	3.7	52
39	Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 496-504.	1.8	50
40	Reproductive Status of Onchocerca volvulus after Ivermectin Treatment in an Ivermectin-NaÃ-ve and a Frequently Treated Population from Cameroon. PLoS Neglected Tropical Diseases, 2014, 8, e2824.	3.0	50
41	Positivity of Antigen Tests Used for Diagnosis of Lymphatic Filariasis in Individuals Without Wuchereria bancrofti Infection But with High Loa loa Microfilaremia. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1417-1423.	1.4	48
42	The Population Biology and Transmission Dynamics of Loa loa. Trends in Parasitology, 2018, 34, 335-350.	3.3	47
43	A Second Population-Based Cohort Study in Cameroon Confirms the Temporal Relationship Between Onchocerciasis and Epilepsy. Open Forum Infectious Diseases, 2020, 7, ofaa206.	0.9	47
44	Dynamics of Onchocerca volvulus Microfilarial Densities after Ivermectin Treatment in an Ivermectin-naÃve and a Multiply Treated Population from Cameroon. PLoS Neglected Tropical Diseases, 2013, 7, e2084.	3.0	43
45	Loiasis: New Epidemiologic Insights and Proposed Treatment Strategy. Journal of Travel Medicine, 2012, 19, 140-143.	3.0	41
46	Lymphatic Vascularisation and Involvement of Lyve-1+ Macrophages in the Human Onchocerca Nodule. PLoS ONE, 2009, 4, e8234.	2.5	39
47	Encephalopathy after Ivermectin Treatment in a Patient Infected with Loa Loa and Plasmodium spp American Journal of Tropical Medicine and Hygiene, 2008, 78, 546-551.	1.4	39
48	Longitudinal Survey of Loa loa Filariasis in Southern Cameroon: Long-Term Stability and Factors Influencing Individual Microfilarial Status. American Journal of Tropical Medicine and Hygiene, 1995, 52, 370-375.	1.4	38
49	Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. Lancet Infectious Diseases, The, 2017, 17, 763-769.	9.1	37
50	Loa loa Microfilarial Periodicity in Ivermectin-Treated Patients: Comparison Between Those Developing and Those Free of Serious Adverse Events. American Journal of Tropical Medicine and Hygiene, 2009, 81, 1056-1061.	1.4	35
51	Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study. Lancet Infectious Diseases, The, 2020, 20, 102-109.	9.1	34
52	Onchocerciasis: The Pre-control Association between Prevalence of Palpable Nodules and Skin Microfilariae. PLoS Neglected Tropical Diseases, 2013, 7, e2168.	3.0	33
53	A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy. Parasites and Vectors, 2006, 5, 6.	1.3	32
54	Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia. Ophthalmic Epidemiology, 2000, 7, 27-39.	1.7	31

#	Article	IF	CITATIONS
55	The Impact of Two Semiannual Treatments with Albendazole Alone on Lymphatic Filariasis and Soil-Transmitted Helminth Infections: A Community-Based Study in the Republic of Congo. American Journal of Tropical Medicine and Hygiene, 2015, 92, 959-966.	1.4	30
56	Measurement of Circulating Filarial Antigen Levels in Human Blood with a Point-of-Care Test Strip and a Portable Spectrodensitometer. American Journal of Tropical Medicine and Hygiene, 2016, 94, 1324-1329.	1.4	30
57	Report of the first international workshop on onchocerciasis-associated epilepsy. Infectious Diseases of Poverty, 2018, 7, 23.	3.7	30
58	Evaluation of the diethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa. Tropical Medicine and International Health, 2006, 12, 061030012640002-???.	2.3	29
59	Genomic Epidemiology in Filarial Nematodes: Transforming the Basis for Elimination Program Decisions. Frontiers in Genetics, 2019, 10, 1282.	2.3	29
60	A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results.  Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 279-289.	1.8	28
61	Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (a^1/425î1/4g/kg) versus current standard dose (150î1/4g/kg). Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 777-785.	1.8	28
62	Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. PLoS Neglected Tropical Diseases, 2021, 15, e0009354.	3.0	28
63	What are the mechanisms associated with post-ivermectin serious adverse events?. Trends in Parasitology, 2006, 22, 244-246.	3.3	27
64	Semi-Quantitative Scoring of an Immunochromatographic Test for Circulating Filarial Antigen. American Journal of Tropical Medicine and Hygiene, 2013, 89, 916-918.	1.4	27
65	Atypical Clinical Manifestations of Loiasis and Their Relevance for Endemic Populations. Open Forum Infectious Diseases, 2019, 6, ofz417.	0.9	27
66	Onchocerciasis-related epilepsy? Prospects at a time of uncertainty. Trends in Parasitology, 2006, 22, 17-20.	3.3	26
67	Single nucleotide polymorphisms in $\hat{l}^2$ -tubulin selected in Onchocerca volvulus following repeated ivermectin treatment: Possible indication of resistance selection. Molecular and Biochemical Parasitology, 2012, 185, 10-18.	1.1	26
68	A case study of risk factors for lymphatic filariasis in the Republic of Congo. Parasites and Vectors, 2014, 7, 300.	2.5	26
69	Projected Number of People With Onchocerciasis–Loiasis Coinfection in Africa, 1995 to 2025. Clinical Infectious Diseases, 2020, 70, 2281-2289.	5.8	25
70	Head nodding syndrome and river blindness: A parasitologic perspective. Epilepsia, 2009, 50, 2325-2326.	5.1	23
71	Associations between filarial and gastrointestinal nematodes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 301-312.	1.8	22
72	Impact of 19Âyears of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon. Parasites and Vectors, 2019, 12, 114.	2.5	22

#	Article	IF	Citations
73	Imported loiasis in Italy: An analysis of 100 cases. Travel Medicine and Infectious Disease, 2014, 12, 713-717.	3.0	21
74	Where next with Loa loa encephalopathy? Data are badly needed. Trends in Parasitology, 2007, 23, 237-238.	3.3	20
75	Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa. EClinicalMedicine, 2020, 28, 100582.	7.1	20
76	Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. American Journal of Tropical Medicine and Hygiene, 2008, 78, 546-51.	1.4	20
77	Significant Association between Epilepsy and Presence of Onchocercal Nodules: Case-Control Study in Cameroon. American Journal of Tropical Medicine and Hygiene, 2012, 86, 557-557.	1.4	19
78	A multi-center field study of two point-of-care tests for circulating Wuchereria bancrofti antigenemia in Africa. PLoS Neglected Tropical Diseases, 2017, 11, e0005703.	3.0	19
79	A comparison of cellular and humoral immune responses to trichuroid derived antigens in human trichuriasis. Parasite Immunology, 2002, 24, 83-93.	1.5	17
80	Impact of repeated ivermectin treatments against onchocerciasis on the transmission of loiasis: an entomologic evaluation in central Cameroon. Parasites and Vectors, 2013, 6, 283.	2.5	17
81	Familial Aggregation and Heritability of Loa loa Microfilaremia. Clinical Infectious Diseases, 2018, 66, 751-757.	5.8	17
82	A new powerful drug to combat river blindness. Lancet, The, 2018, 392, 1170-1172.	13.7	16
83	Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa. International Health, 2018, 10, i49-i53.	2.0	16
84	Effect of a Single Standard Dose (150–200 μg/kg) of Ivermectin on <i>Loa loa</i> Microfilaremia: Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2019, 6, ofz019.	0.9	15
85	The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. PLoS Neglected Tropical Diseases, 2020, 14, e0008322.	3.0	15
86	A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa–coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon. Clinical Infectious Diseases, 2020, 70, 1628-1635.	5.8	14
87	Onchocerciasis, Cysticercosis, and Epilepsy. American Journal of Tropical Medicine and Hygiene, 2008, 79, 643-644.	1.4	14
88	Antibody responses in onchocerciasis as a function of age and infection intensity. Parasite Immunology, 2001, 23, 509-516.	1.5	13
89	Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. Acta Tropica, 2011, 120, S91-S99.	2.0	13
90	Performance of two serodiagnostic tests for loiasis in a Non-Endemic area. PLoS Neglected Tropical Diseases, 2020, 14, e0008187.	3.0	13

#	Article	IF	Citations
91	Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial. Clinical Infectious Diseases, 2022, 75, 19-27.	5.8	13
92	A Controlled Trial to Assess the Effect of Quinine, Chloroquine, Amodiaquine, and Artesunate on Loa loa Microfilaremia. American Journal of Tropical Medicine and Hygiene, 2010, 82, 379-385.	1.4	12
93	Onchocerca volvulus transmission in the Mbam valley of Cameroon following 16Âyears of annual community-directed treatment with ivermectin, and the description of a new cytotype of Simulium squamosum. Parasites and Vectors, 2021, 14, 563.	2.5	12
94	La résistance de Onchocerca volvulus à livermectine: une éventualité à considérer. Annales De L'Institut Pasteur / Actualités, 1999, 10, 81-91.	0.1	11
95	Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo. Parasites and Vectors, 2019, 12, 162.	2.5	11
96	Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually. Parasites and Vectors, 2020, 13, 258.	2.5	11
97	Detection of DNA of filariae closely related to Mansonella perstans in faecal samples from wild non-human primates from Cameroon and Gabon. Parasites and Vectors, 2020, 13, 313.	2.5	11
98	African Programme for Onchocerciasis Control (APOC): sociological study in three foci of central Africa before the implementation of treatments with ivermectin (Mectizan®). Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, $101$ , $674$ - $679$ .	1.8	10
99	Loiasis with Peripheral Nerve Involvement and Spleen Lesions. American Journal of Tropical Medicine and Hygiene, 2011, 84, 733-737.	1.4	10
100	Analysis of Nematode Motion Using an Improved Light-Scatter Based System. PLoS Neglected Tropical Diseases, 2015, 9, e0003523.	3.0	8
101	Helminthic Diseases: Onchocerciasis and Loiasis. , 2017, , 576-587.		8
102	Onchocerciasis, cysticercosis, and epilepsy. American Journal of Tropical Medicine and Hygiene, 2008, 79, 643-4; author reply 644-5.	1.4	8
103	Genetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary study. Parasites and Vectors, 2004, 3, 4.	1.3	7
104	Familial Aggregation and Heritability of <i>Wuchereria bancrofti </i> Infection. Journal of Infectious Diseases, 2016, 214, 587-594.	4.0	7
105	Results from two cohort studies in Central Africa show that clearance of Wuchereria bancrofti infection after repeated rounds of mass drug administration with albendazole alone is closely linked to individual adherence. Clinical Infectious Diseases, 2021, 73, e176-e183.	5.8	7
106	Effects of an injectable long-acting formulation of ivermectin on <i>Onchocerca ochengi</i> in zebu cattle. Parasite, 2020, 27, 36.	2.0	7
107	Unusual Localization of Blood-Borne <i>Loa loa</i> Microfilariae in the Skin Depends on Microfilarial Density in the Blood: Implications for Onchocerciasis Diagnosis in Coendemic Areas. Clinical Infectious Diseases, 2021, 72, S158-S164.	5.8	6
108	Epilepsy in the Sanagaâ€Mbam valley, an onchocerciasisâ€endemic region in Cameroon: electroclinical and neuropsychological findings. Epilepsia Open, 2021, 6, 513-527.	2.4	6

#	Article	IF	Citations
109	Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat―Strategy in <i>Loa loa</i> Co-endemic Areas. Clinical Infectious Diseases, 2021, 72, e1047-e1055.	5.8	6
110	Community-based door to door census of suspected people living with epilepsy: empowering community drug distributors to improve the provision of care to rural communities in Cameroon. BMC Public Health, 2020, 20, 871.	2.9	5
111	Absence of an Association Between Plasmodium falciparum Infection and Post-Ivermectin Loa-Related Non-Neurologic Serious Adverse Events. American Journal of Tropical Medicine and Hygiene, 2014, 90, 335-338.	1.4	4
112	Erythropoietin for treating post-ivermectin Loa-related serious adverse events?. Trends in Parasitology, 2010, 26, 4-5.	3.3	3
113	Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia. Ophthalmic Epidemiology, 2000, 7, 27-39.	1.7	3
114	Limitations of PCR detection of filarial DNA in human stools from subjects non-infected with soil-transmitted helminths. Parasite, 2021, 28, 47.	2.0	2
115	Knowledge/perception and attitude/practices of populations of two first-line communities of the Centre Region of Cameroon regarding onchocerciasis and black fly nuisance and bio-ecology. Parasites and Vectors, 2021, 14, 546.	2.5	2
116	Microfilariae Classification Using Multiple Classifiers for Color and Shape Features. Open Engineering, 2016, $6$ , .	1.6	1
117	Impact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment. American Journal of Tropical Medicine and Hygiene, 2022, 106, 729-731.	1.4	1
118	A strong effect of individual compliance with mass drug administration for lymphatic filariasis on sustained clearance of soil-transmitted helminth infections. Parasites and Vectors, 2021, 14, 310.	2.5	0
119	Effect of Lymphatic Filariasis and Hookworm Infection on Pregnancy Course and Outcome in Women Living in the Democratic Republic of the Congo. American Journal of Tropical Medicine and Hygiene, 2021, 104, 2074-2081.	1.4	0
120	Historical overview and geographical distribution of neglected tropical diseases amenable to preventive chemotherapy in the Republic of the Congo: A systematic review. PLoS Neglected Tropical Diseases, 2022, 16, e0010560.	3.0	0